GMAB

Genmab AS

29.18 USD
+0.07 (+0.24%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Genmab AS stock is up 5.61% since 30 days ago. The next earnings date is Feb 14, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 4 February’s closed higher than January. In the last 1 Unusual Options Trades, there were 1 CALL. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
09 Jan 20:28 16 Aug, 2024 30.00 CALL 75 0

About Genmab AS

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases. The company markets DARZALEX, a human monoclonal antibody for the. treatment of patients with multiple myeloma (MM) and ofatumurnab for. multiple sclerosis (CLL) and multiple sclerosis. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers.

  • Truist Securities
    Tue Feb 20, 09:25
    buy
    confirm
  • HC Wainwright & Co.
    Tue Feb 20, 07:20
    buy
    confirm
  • HC Wainwright & Co.
    Mon Jan 29, 06:39
    buy
    confirm